Article

Multidisciplinary team studies blinding diseases

Boston-The Schepens Eye Research Institute will form teams of basic and clinical researchers from many disciplines to study blinding eye diseases under a unique grant available from the National Institutes of Health (NIH).

Boston-The Schepens Eye Research Institute will form teams of basic and clinical researchers from many disciplines to study blinding eye diseases under a unique grant available from the National Institutes of Health (NIH).

The program, part of the "NIH Road-map" that seeks to find new ways to solve problems outside traditional research, will create a "think tank" of researchers from Schepens, Massachusetts Eye and Ear Infirmary, Harvard Medical School, and other Harvard teaching hospitals. Researchers will include those studying Alzheimer's disease, rheumatoid arthritis, and heart disease.

The 3-year, nearly $2.2 million grant will fund the planning and piloting phase of what will ultimately be an interdisciplinary research center.

Researchers hope the work will turn up ideas for addressing incurable diseases in other areas of the body.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.